EYES - Second Sight Medical Products, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7932
-0.0309 (-3.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8241
Open0.8572
Bid0.8000 x 4000
Ask0.8500 x 1000
Day's Range0.7800 - 0.8572
52 Week Range0.6350 - 2.5800
Volume284,030
Avg. Volume510,469
Market Cap60.55M
Beta (3Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.5400
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Second Sight Medical Products, Inc. Announces $40 Million Rights Offering of Units and Two Year Extension of Warrants (EYESW) Expiration Date

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced a rights offering to raise $40 million. Holders of our common stock on January 15, 2019, the record date, will be able to participate in the rights offering.

  • GlobeNewswire10 days ago

    Second Sight Reports Fourth Quarter 2018 Business Update

    -- Full Year 2018 net revenue estimated to be in the range of $6.5-$6.9 million -- -- 6th Orion patient scheduled for implantation at Baylor Medical Center -- LOS ANGELES,.

  • GlobeNewswire28 days ago

    Second Sight to Present at Digital Medicine and Medtech Showcase 2019

    LOS ANGELES, Dec. 20, 2018 -- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual.

  • GlobeNewswirelast month

    Second Sight Completes $3 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into a stock purchase agreement effective December 12, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors of Second Sight, for the purchase of  3,275,100 shares of common stock priced at $0.916 per share, the last reported sale price of the common stock on the effective date. This placement of common stock is anticipated to yield gross proceeds of approximately $3 million to the Company.

  • Second Sight Medical Products Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Second Sight Medical Products Sees Hammer Chart Pattern: Time to Buy?

    Second Sight Medical Products has been struggling lately, but the selling pressure may be coming to an end soon

  • Thomson Reuters StreetEventslast month

    Edited Transcript of EYES earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Second Sight Medical Products Inc Earnings Call

  • GlobeNewswire2 months ago

    Second Sight to Present at the 11th Annual LD Micro Main Event Conference in Los Angeles on Wednesday, December 5th

    The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.secondsight.com, under the Investor Relations section. Conference participation is by invitation only and registration is mandatory.

  • Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates

    Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 21.43% and -9.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Second Sight Medical Products: 3Q Earnings Snapshot

    The Sylmar, California-based company said it had a loss of 12 cents per share. Losses, adjusted for stock option expense and non-recurring costs, were 11 cents per share. The maker of camera-based retinal ...

  • GlobeNewswire2 months ago

    Second Sight Announces Final 2019 Medicare Hospital Outpatient Payment Rate for the Argus II Retinal Prosthesis System

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its Medicare hospital outpatient payment rate of $152,500 for the Argus® II Retinal Prosthesis System (Argus II) and the associated surgical implantation procedure for calendar year 2019.

  • Business Wire3 months ago

    Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call

    Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its 2018 third quarter financial results on Wednesday, November 7, 2018, after the close of the U.S. financial markets. In 2016, the Company published five year results.

  • Business Wire3 months ago

    Second Sight Completes $4 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that it has entered into a stock purchase agreement effective October 18, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors of Second Sight, for the purchase of 2,467,727 shares of common stock priced at $1.62 per share, the last reported sale price of the common stock on the effective date. This placement of common stock is anticipated to yield gross proceeds of approximately $4 million to the Company.

  • Business Wire4 months ago

    Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development

    Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today announced that the Company has received a $1.6 million grant (with the intent to fund $6.3 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in January 2018.

  • Business Wire4 months ago

    Second Sight Appoints Pat Ryan Chief Operating Officer

    Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Materials, Quality Assurance, and Information Technology. “Pat brings a wealth of knowledge from both large and small medical device firms, and we are delighted to welcome him to the Second Sight team.

  • Business Wire5 months ago

    Second Sight to Present at Investor Conferences in September

    The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.secondsight.com, under the Investor Relations section. Second Sight Medical Products, Inc. develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

  • Second Sight Medical Products (EYES): Moving Average Crossover Alert
    Zacks5 months ago

    Second Sight Medical Products (EYES): Moving Average Crossover Alert

    Second Sight Medical Products, Inc. (EYES) could be a stock to avoid from a technical perspective

  • Business Wire5 months ago

    Second Sight Completes $5.0 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

    Second Sight Medical Products, Inc. (EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that it has entered into a stock purchase agreement effective August 14, 2018 with entities beneficially owned by Gregg Williams, Chairman of the Board of Directors, for the purchase of 3,225,807 shares of common stock priced at $1.55 per share, the last reported sale price of the common stock on the effective date. This placement of common stock is anticipated to yield gross proceeds of approximately $5,000,000 to the Company. No warrants or discounts were provided and no placement agent or investment banking fees were incurred in connection with this transaction.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of EYES earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Second Sight Medical Products Inc Earnings Call

  • Associated Press5 months ago

    Second Sight Medical Products: 2Q Earnings Snapshot

    The Sylmar, California-based company said it had a loss of 12 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 11 cents per share. The maker of camera-based retinal ...

  • Business Wire5 months ago

    Second Sight Reports Second Quarter 2018 Financial Results

    -- Achieves program milestones as Orion clinical and R&D activities advance --

  • ACCESSWIRE5 months ago

    Second Sight Medical Products, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Second Sight Medical Products, Inc. (NASDAQ: EYES ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 ...